Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.
This phase I/II study is evaluating how safe, tolerable and effective a new targeted therapy (AZD9574) is alone, or in combination with chemotherapy (temozolomide) in people with advanced solid cancers
Status : Recruiting
This phase I study is evaluating how safe, tolerable and effective a new cancer drug (BGB-24714) is alone, and in combination with chemotherapy (paclitaxel) in people with advanced or metastatic solid cancers
This phase I/II study is evaluating how safe, tolerable and effective a new targeted therapy (PBI-200) is in people with NTRK-fusion-positive advanced or metastatic solid cancers
This phase I study is evaluating how safe, tolerable and effective a new cancer drug (BGB-B167) is alone, and in combination with targeted therapy (tislelizumab) in people with advanced solid cancers
This phase I study is trying to understand how safe and tolerable a targeted cancer drug (trastuzumab deruxtecan) is in combination with other anti-cancer drugs in people with metastatic breast cancer
This Phase II trial is trying to determine how effective using a combination of cancer drugs (carboplatin, gemcitabine, bevacizumab and atezolizumab) is in people with early relapsed triple negative breast cancer
This phase I/II trial is evaluating various immunotherapy based treatment combinations as a way of treating patients with a Triple Negative Breast Cancer (TNBC) that has spread to other parts of the body
This phase II trial is evaluating the effectiveness of delivering different combinations of hormone therapy (including letrozole, prometrium and tamoxifen) prior to surgery in postmenopausal women with early-stage breast cancer
This phase Ib/II trial aims to explore the safety, tolerability, and anti-tumour activity of a targeted cancer therapy in patients with breast cancer that has not previously been treated using chemotherapy and has spread to other parts of the body
This phase I study is trying to understand how safe, tolerable and effective a new targeted therapy (PF-07248144) is alone, or combined with either hormone therapy (fulvestrant) or hormone therapy (letrozole) and another targeted therapy (palbociclib), in people with breast cancer, prostate cancer or non-small cell lung cancer
Looking for a trial? Use the search functionality to find the trial you are finding.